June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Comparison of the Total Amount of Triamcinolone Acetonide Delivered Via Suprachoroidal or Intravitreal Administration
Author Affiliations & Notes
  • Brian Burke
    Clearside Biomedical, Raleigh, NC
  • Rozemarijn Verhoeven
    Clearside Biomedical, Raleigh, NC
  • Samirkumar Patel
    Clearside Biomedical, Raleigh, NC
  • Footnotes
    Commercial Relationships Brian Burke, Clearside Biomedical (E); Rozemarijn Verhoeven, Clearside Biomedical (E); Samirkumar Patel, Clearside Biomedical (E), Clearside Biomedical (I), Clearside Biomedical (P)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5062. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Brian Burke, Rozemarijn Verhoeven, Samirkumar Patel; Comparison of the Total Amount of Triamcinolone Acetonide Delivered Via Suprachoroidal or Intravitreal Administration. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5062.

      Download citation file:


      © 2017 Association for Research in Vision and Ophthalmology.

      ×
  • Supplements
Abstract

Purpose: The purpose of this study was to compare the total amount of triamcinolone acetonide (TA) delivered into a pig eye when injected into the suprachoroidal space using a Clearside Biomedical proprietary microneedle or into the vitreous using a standard 30 gauge needle.

Methods: Whole pig cadaver eyes (Sioux-Preme Packing) enucleated within 24 hours after death were used for all injections. Intravitreal and suprachoroidal injections of TA were performed using Triesence® (Alcon Labs). Intravitreal injections were performed using a 30 g needle (Becton-Dickinson) and suprachoroidal injections were performed using a Clearside Biomedical proprietary microneedle. 1 mL syringes (Becton-Dickinson) were loaded with the required amount of Triesence® at each of the three volumes assessed: 50, 100, and 150 µL (2, 4, and 6 mg, respectively). The residual amount of TA present in the syringe/needle assembly after injection was determined by RP-HPLC. The total amount of TA delivered to the eye for each dose volume was determined as the difference in the total amount loaded into a syringe before injection into the pig eye versus the residual amount of TA recovered from the syringe/needle assembly after injection.

Results: Average total dose administered following 50, 100 and 150 µL TA injected into the suprachoroidal space ranged from 86-92% of the target dose level, while average total dose administered following 50 and 100 µL TA injected into the vitreous ranged from 88-89%. Virtually no difference was observed between the two routes of administration and needles for each volume.

Conclusions: The target dose level of TA can be consistently delivered into the SCS using a microneedle or into the vitreous using a 30 g needle. Total amount of TA delivered was similar between the two administration routes.

Keywords: 561 injection • 452 choroid • 763 vitreous  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×